turoctocog alfa + turoctocog alfa
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Congenital Bleeding Disorder
Conditions
Congenital Bleeding Disorder, Haemophilia A
Trial Timeline
Jun 1, 2010 → Nov 1, 2011
NCT ID
NCT01138501About turoctocog alfa + turoctocog alfa
turoctocog alfa + turoctocog alfa is a phase 3 stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01138501. Target conditions include Congenital Bleeding Disorder, Haemophilia A.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02938585 | Phase 3 | Completed |
| NCT01692925 | Phase 1 | Completed |
| NCT01138501 | Phase 3 | Completed |
| NCT00984126 | Phase 3 | Completed |
Competing Products
20 competing products in Congenital Bleeding Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Pasireotide 0.6Mg Solution for Injection + Saline Solution | Novartis | Phase 2 | 52 |
| Sandostatine LP | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| catridecacog + recombinant factor XIII | Novo Nordisk | Phase 1 | 32 |
| activated recombinant human factor VII | Novo Nordisk | Phase 2 | 51 |
| turoctocog alfa pegol | Novo Nordisk | Phase 3 | 76 |
| recombinant factor XIII | Novo Nordisk | Pre-clinical | 22 |
| activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting | Novo Nordisk | Phase 1 | 32 |
| Advate® + turoctocog alfa | Novo Nordisk | Phase 1 | 32 |
| nonacog beta pegol | Novo Nordisk | Phase 3 | 76 |